Session Details

[PC1]Corporate Exhibition

Mon. Mar 2, 2026 6:30 PM - 7:30 PM JST
Mon. Mar 2, 2026 9:30 AM - 10:30 AM UTC
Corporate Exhibition(Ohwada foyer)

[PC1-01]Advanced technologies for mRNA-based therapeutics
- saRNA and HARNATM, new mRNA optimizing -

*Ken Miyajima1, Akiko Yanagiya1, Rena Akahori2, Tomohiro Sawadaishi1, Aoi Onuma1, Yanwen Feng1, Satoshi Abe1, Jun Nihira1, Tetsuo Yoshida1, Kazuyuki Nakashima1 (1. ARCALIS, Inc. (Japan), 2. Hitachi, Ltd., Research development group (Japan))
Comment()

[PC1-02]Exibition for Bioprocess support materials

*Yoshiaki Ogawa1, Sadao Ozawa1, Yasuhiko Kurisu1, Yosuke Imamura1 (1. Merck Ltd. (Japan))
Comment()

[PC1-03]Formulation development of Intranasal Vaccine and design of spray device for Intranasal Vaccine

*Shota Masuda1, Yasuyuki Shiraishi1, Taiji Horita1, Takashi Kamishita2, Natsumi Kodake2, Toshiaki Takagi2, Takashi Miyazaki2 (1. Taisei Kako Co.,Ltd. (Japan), 2. TOKO YAKUHIN KOGYO CO., LTD. (Japan))
Comment()

[PC1-04]Transdermal Vaccination System using a Needle-free Intraepidermal Administration, PassPort Microporation Device

*Hirotoshi Adachi1,2, Uros Kascak1 (1. PassPort Technologies, Inc. (USA), 2. PassPort Technologies Japan, Inc. (Japan))
Comment()

[PC1-05]Clinical research service introduction

*Akira Ikeda1 (1. EPS Corporation (Japan))
Comment()

[PC1-06]SMART (Simple MucoAdhesive Release Technology) as a Platform for Nasal Vaccine Development

*Satoshi Nakano1, Yo Sonoda1, Ryota Ise1 (1. TR Business Division, Shin Nippon Biomedical Laboratories, Ltd. (Japan))
Comment()

[PC1-07]Product introduction (Transient expression medium for CHO cells, Mpox virus detection kit: GENECUBE MPXV)

*Hiroyuki Hata1 (1. Kyokuto pharmaceutical industrial Co., Ltd. (Japan))
Comment()

[PC1-08]Introduction to Adtec Co., Ltd. — A Diagnostic Test Kit Manufacturer

*Yuichiro Kida1, Kenta Fukuda1, Nobiko Takayama1, Takateru Nozaki1, MIsako Iwai1, Kaoru Kobayashi1, Katsuyoshi Takayama1 (1. Research and Development Department, ADTEC Co.,LTD (Japan))
Comment()

[PC1-09]Toward next-generation vaccine antigens: a silkworm–baculovirus expression platform

*Tomoki Sasaki1, Keiichi Esaki1, Yo Nakahara1, Masahiro Taniguchi1 (1. KAICO Ltd. (Japan))
Comment()

[PC1-10]Company introduction

*Akihito Sawada1, Yuusuke Okada1, Takeru Yamakawa1 (1. Infectious Disease Control Labs, Drug Discovery Department Meiji Seika Pharma Co., Ltd. (Japan))
Comment()

[PC1-11]Introduction to the Common Marmoset

*Hiroshi Ikeda1 (1. CLEA-Japan,Inc. (Japan))
Comment()

[PC1-12]Global Biopharma Index 2025 - Manufacturing Agility

*Kensuke Ono1, Mitsuyasu Miwa1 (1. Global LifeScience Technologies Japan (Japan))
Comment()

[PC1-13]Cancel

Comment()

[PC1-14]World highest level aseptic parenteral viall filling system.

*ZENYA YANASE1 (1. Steri Japan Co.Ltd (Japan))
Comment()

[PC1-15]Introducing the RTU (Ready to use) syringe line

*Seiji Fukuoka1 (1. HIKARI Pharmaceutical CO.,LTD (Japan))
Comment()

[PC1-16]Vaccine Business in Daiichi Sankyo

*Ryuji Hashimoto1 (1. Daiichi Sankyo Co., Ltd. Vaccine Business Department (Japan))
Comment()